Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cryoport, Inc. (CYRX)

Cryoport raises 2026 revenue guidance to $192 million-$196 million on 16% Q1 growth

Positive Impact 4 of 5 guidance Written later

Cryoport reported first-quarter 2026 revenue of $47.8 million, up 16% from a year earlier, and raised its full-year 2026 revenue guidance to $192 million to $196 million. Net loss narrowed to $10.5 million from $12.0 million, but the loss from continuing operations widened to $9.4 million from $6.7 million.

Key points

  • Q1 2026 total revenue was $47.8 million, up 16% year-over-year from $41.0 million.
  • Commercial cell and gene therapy revenue rose 26% to $9.1 million.
  • Net loss per share attributable to common stockholders was $0.25, compared with $0.28 in Q1 2025.
  • Cash, cash equivalents and short-term investments totaled $403.6 million as of March 31, 2026.

The filing

CompanyCryoport, Inc. (CYRX)
Form8-K, current report
Filed with the SECMay 4, 2026, 4:30 PM ET
Accession number0001104659-26-054942

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.